Nudge Therapeutics

Founded in 2019 and based in Wisconsin, US, Nudge Therapeutics specializes in innovative small molecule therapies that target the cGAS/STING pathway, essential for enhancing cancer immunity and managing autoimmune diseases like lupus. In January 2025, VERALOX Therapeutics Inc. , a portfolio company of JDRF T1D Fund, Maryland Momentum Fund, Middleland Capital, Sanofi Ventures, Alexandria Venture Investments, Alumni Ventures Group, and others, acquired Nudge Therapeutics. The firm’s main product offerings include two distinct chemotypes of cGAS antagonists demonstrating nanomolar potency and promising drug-like properties.

These small molecules modulate the immune response by stimulating the cGAS/STING pathway to enhance tumor immunity while alleviating autoimmune symptoms. Their therapeutic candidates address significant unmet medical needs in oncology and immunology, serving healthcare providers, hospitals, and research institutions in the United States and Europe.   Nudge Therapeutics generates revenue through strategic partnerships and collaborations with pharmaceutical companies, academic institutions, and contract research organizations. Their revenue model is primarily B2B, involving licensing agreements and joint development arrangements that facilitate the advancement of their therapeutic candidates through clinical trials.

They focus on their proprietary cGAS antagonists and other therapeutics, which are positioned to enter various stages of clinical testing. The revenue model includes milestone payments and royalties from successful commercialization outcomes as their products progress through the regulatory landscape.